Arterys Cardio DL vs Imbio PHA (4.0.0)
AI Verdict
Choose Arterys Cardio DL if…
Choose Arterys Cardio DL if your primary need is a comprehensive and highly detailed analysis of cardiac MRI studies. This tool excels at providing automated, editable ventricle segmentations, 4D Flow post-processing for blood flow visualization, and quantitative delayed enhancement analysis, significantly reducing interpretation time for complex MRI cases.
View Arterys Cardio DL →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if you require rapid, automated assessment of cardiac structures specifically from CT pulmonary angiogram (CTPA) scans. This tool is ideal for aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension by automatically measuring key cardiac diameters and calculating critical ratios like RV/LV and PA/Ao.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Arterys Cardio DL | Imbio PHA (4.0.0) |
|---|---|---|
| Deployment | Cloud-based (SaaS), integrates with existing PACS or EHR, web-based zero-footprint viewer (Mac, PC, tablet, phone). [4, 7, 9, 13, 27] | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA emphasizes seamless integration with native DICOM tools and workflows, delivering annotated images and summary reports directly into the PACS without additional steps for the physician. This focus on minimal disruption to existing clinical practices and fully automated results gives it a slight edge in usability.
Clinical Value
Arterys Cardio DLArterys Cardio DL offers a broader and more advanced suite of quantitative analyses for cardiac MRI, including 4D Flow and Quantitative Delayed Enhancement, which significantly enhances diagnostic accuracy and reduces interpretation time for complex cardiac studies. Its ability to reduce patient scan times, particularly for children, also adds substantial clinical benefit.
Pricing & Value
TieBoth Arterys Cardio DL and Imbio PHA explicitly state 'contact for pricing,' indicating a lack of transparent pricing information. Without specific cost details, it is impossible to conduct a head-to-head comparison of their financial value.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA offers superior enterprise readiness due to its flexible deployment options, including cloud, on-premise, or via partners, which caters to a wider range of institutional IT infrastructures and data security preferences. This contrasts with Arterys Cardio DL's solely cloud-based deployment.
Innovation
Arterys Cardio DLArterys Cardio DL demonstrates greater innovation by being recognized as the world's first internet platform for medical imaging and the first FDA-cleared cloud-based deep learning software for clinical use. Its advanced features like 4D Flow and Quantitative Delayed Enhancement, coupled with a self-optimizing deep learning model, represent a more pioneering approach to medical imaging AI.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA provides clear and detailed information regarding its support channels, including phone and email contacts, an online case submission form, and explicit mention of readily available user manuals and product documentation. Arterys Cardio DL's support and documentation details are less explicitly outlined in the available information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Arterys Cardio DL | Imbio PHA (4.0.0) |
|---|---|---|
| Name | Arterys Cardio DL | Imbio PHA (4.0.0) |
| Description | FDA-cleared, cloud-based AI software that provides automated, editable ventricle segmentations for cardiac MRI analysis, drastically reducing interpretation time and enhancing diagnostic accuracy. | FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. |
| Company | ARTERYS | Imbio |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI, Radiology & Imaging AI |
| Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
| Key Features | Automated ventricle segmentations for cardiac MRI, Deep learning algorithms for image analysis, Cloud-based platform for accessibility and performance, Vendor-agnostic compatibility, Rapid analysis (seconds vs. 30-60 minutes), Editable automated contours, 4D Flow post-processing for blood flow visualization and quantification, Quantitative Delayed Enhancement analysis | Automated measurement of right and left ventricle diameters, Automated measurement of main pulmonary artery and aorta diameters, Calculates RV/LV and PA/Ao ratios, Utilizes artificial intelligence algorithms for anatomical identification and measurement, Generates annotated DICOM images, Provides summary reports in PDF format, Integrates with native DICOM tools and workflows, Rapid, fully-automated assessment (typically in minutes) |
Videos
Demos, reviews, and walkthroughs featuring Arterys Cardio DL and Imbio PHA (4.0.0).